The Complete Guide to GLP-1 Receptor Agonists: From Semaglutide to Retatrutide

Introduction: The Expanding Universe of Incretin-Based Therapies

The success of semaglutide has catalyzed an explosion of research and development in incretin-based therapeutics. What was once a relatively narrow field focused on GLP-1 receptor agonism for type 2 diabetes has expanded into a vast and rapidly evolving landscape encompassing single, dual, and triple receptor agonists targeting multiple metabolic pathways simultaneously. The compounds under investigation range from incremental improvements on existing molecules to fundamentally novel multi-agonist approaches that may redefine the upper limits of pharmacological weight reduction and metabolic improvement.

This guide provides a comprehensive overview of the major GLP-1 receptor agonists and related multi-agonist compounds currently in clinical use or advanced development. We examine each compound's mechanism, clinical data, and position in the broader therapeutic landscape. This information is intended for educational purposes only and does not constitute medical advice.

Understanding the Incretin System: GLP-1, GIP, Glucagon, and Amylin

Before examining individual compounds, it is essential to understand the signaling pathways that these agents target. The incretin system and related metabolic hormones include several key players:

• GLP-1 (Glucagon-Like Peptide-1): Secreted by intestinal L-cells, GLP-1 enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite. It is the foundational target of this entire drug class.
• GIP (Glucose-Dependent Insulinotropic Polypeptide): Secreted by intestinal K-cells, GIP was long regarded as the "forgotten incretin" because early research suggested it was less therapeutically useful. However, newer understanding has revealed that GIP receptor agonism can complement GLP-1 effects on insulin secretion, may have direct effects on adipose tissue and brain, and appears to enhance tolerability when combined with GLP-1 agonism. The role of GIP remains somewhat paradoxical and is an active area of debate.
• Glucagon: Primarily secreted by pancreatic alpha cells, glucagon stimulates hepatic glucose production and promotes lipolysis and energy expenditure. While glucagon's glucose-raising effects might seem counterproductive, controlled glucagon receptor agonism in combination with GLP-1 agonism may enhance total energy expenditure and fat oxidation, potentially increasing weight loss without compromising glycemic control.
• Amylin: Co-secreted with insulin from pancreatic beta cells, amylin slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety through central mechanisms. Amylin signaling represents a complementary pathway to GLP-1 for appetite regulation.

Semaglutide: The Single GLP-1 Agonist That Started a Revolution

Mechanism and Key Properties

Semaglutide is a single GLP-1 receptor agonist with 94% homology to native human GLP-1. Its key structural modifications, including alpha-aminoisobutyric acid at position 8 and a C-18 fatty di-acid chain at position 26, confer DPP-4 resistance and strong albumin binding, yielding a half-life of approximately one week. It is available as a once-weekly subcutaneous injection (Ozempic for diabetes, Wegovy for weight management) and a once-daily oral tablet (Rybelsus for diabetes).

Efficacy Data Summary

In the STEP trial program, semaglutide 2.4 mg subcutaneously once weekly produced mean weight reductions of approximately 14.9% (STEP 1), 9.6% (STEP 2, in type 2 diabetes), and 16.0% (STEP 3, with intensive behavioral therapy) at 68 weeks. HbA1c reductions in diabetes populations have consistently ranged from 1.5% to 1.8%. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease without diabetes.

Market Position

Semaglutide remains the market leader and scientific benchmark in this class, with combined annual revenues exceeding $29.3 billion across its three branded formulations. Novo Nordisk's position as the dominant player in the GLP-1 market has made it one of the most valuable pharmaceutical companies globally. However, competition from dual and triple agonists is intensifying.

Tirzepatide: The Dual GIP/GLP-1 Agonist That Raised the Bar

What Is Tirzepatide?

Tirzepatide, developed by Eli Lilly, is a first-in-class dual GIP and GLP-1 receptor agonist. It is a synthetic peptide of 39 amino acids based on the native GIP sequence, with modifications that confer activity at both the GIP and GLP-1 receptors. The molecule incorporates a C-20 fatty di-acid chain that enables strong albumin binding and once-weekly dosing, analogous to the approach used in semaglutide but applied to a fundamentally different peptide backbone.

Tirzepatide shows approximately 5-fold selectivity for the GIP receptor relative to the GLP-1 receptor, meaning it is primarily a GIP agonist with significant GLP-1 agonist activity. This distinguishes it from semaglutide, which is a pure GLP-1 agonist. The rationale for dual agonism is that GIP and GLP-1 signaling may produce synergistic effects on insulin secretion, appetite regulation, and energy metabolism through complementary central and peripheral mechanisms.

FDA-Approved Formulations

• Mounjaro (Eli Lilly): Approved for type 2 diabetes in May 2022. Available as once-weekly subcutaneous injection in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
• Zepbound (Eli Lilly): Approved for chronic weight management in November 2023. Same molecule and dose options, marketed under a separate brand name for the obesity indication.

Efficacy Data: Surpassing Semaglutide

Tirzepatide's clinical data has been remarkable, consistently demonstrating weight loss that numerically exceeds that achieved with semaglutide. Key findings include:

• SURMOUNT-1: In adults with obesity or overweight without diabetes, tirzepatide produced mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) at 72 weeks, compared to 3.1% with placebo. Notably, over one-third of participants in the 15 mg group achieved 25% or greater weight loss, and some participants achieved weight reductions exceeding 30%.
• SURMOUNT-2: In adults with type 2 diabetes and obesity, tirzepatide 15 mg achieved approximately 14.7% weight loss at 72 weeks, with HbA1c reductions of approximately 2.4%.
• SURPASS-2 (head-to-head vs. semaglutide): Tirzepatide 15 mg demonstrated significantly greater HbA1c reduction (-2.46%) compared to semaglutide 1 mg (-1.86%) and significantly greater weight loss (-12.4 kg vs. -6.2 kg) at 40 weeks. This was a head-to-head trial, though it compared tirzepatide's highest dose to semaglutide's then-standard diabetes dose rather than the 2.4 mg weight management dose.

Revenue and Market Impact

Tirzepatide has achieved one of the fastest revenue ramp-ups in pharmaceutical history, reaching approximately $16.5 billion in annual revenue. Eli Lilly's market capitalization has surged on the strength of tirzepatide and its pipeline, making it the most valuable pharmaceutical company in the world at various points. The competition between Novo Nordisk's semaglutide franchise and Lilly's tirzepatide franchise has become one of the defining commercial dynamics in the pharmaceutical industry.

Retatrutide: The Triple Agonist Frontier

What Is Retatrutide?

Retatrutide (LY3437943), also developed by Eli Lilly, represents the next frontier in incretin-based therapeutics as a triple agonist of GIP, GLP-1, and glucagon receptors. This molecule activates three distinct metabolic hormone receptors simultaneously, a conceptual leap from the single-agonist approach of semaglutide and the dual-agonist approach of tirzepatide.

The rationale for adding glucagon receptor agonism to the GIP/GLP-1 foundation is that glucagon activates pathways that increase energy expenditure, promote hepatic lipid oxidation, and stimulate thermogenesis. While glucagon's hyperglycemic effects might seem problematic, the concurrent GLP-1 and GIP agonism is designed to counterbalance the glucose-raising effects of glucagon, resulting in a net favorable metabolic profile with enhanced total energy expenditure and fat mobilization.

Phase 2 Trial Results: 23.7% Weight Reduction

The phase 2 trial of retatrutide, published in the New England Journal of Medicine, produced results that exceeded anything previously reported for a pharmacological weight loss intervention:

• At the highest dose (12 mg), participants achieved a mean weight reduction of 23.7% at 48 weeks, with the weight loss trajectory still declining at study end, suggesting that the maximum effect had not yet been reached.
• At the 12 mg dose, approximately 26% of participants achieved 30% or greater weight loss, and some individuals lost more than 35% of their body weight.
• The 48-week timeframe is notably shorter than the 68-72 weeks used in semaglutide and tirzepatide pivotal trials, and the weight loss curve had not yet plateaued, suggesting that longer treatment duration could yield even greater reductions.
• Glycemic improvements were similarly impressive, with HbA1c reductions up to approximately 2.2% in the subgroup with type 2 diabetes.
• Hepatic fat reductions of up to 81% were observed, suggesting particular promise for NAFLD/MASH.

Phase 3 Development

Based on these exceptional phase 2 results, retatrutide has advanced into a large phase 3 clinical trial program (the TRIUMPH program). If phase 3 results confirm the phase 2 findings, retatrutide could represent a significant advance over existing treatments. However, it is important to note that phase 2 results do not always fully replicate in larger phase 3 populations, and the full safety profile of triple agonism over longer durations requires careful evaluation.

Unique Aspects of Triple Agonism

The glucagon receptor agonist component of retatrutide distinguishes it from both semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1). The glucagon component may offer specific advantages:

• Increased energy expenditure: Glucagon activates hepatic and extrahepatic pathways that increase basal metabolic rate and thermogenesis, meaning that weight loss with retatrutide may involve a greater contribution from increased caloric expenditure rather than relying solely on reduced caloric intake.
• Enhanced hepatic fat reduction: Glucagon promotes hepatic lipid oxidation and may account for the dramatic liver fat reductions observed in the phase 2 trial.
• Potential lean mass preservation: Some researchers have hypothesized that the energy-expenditure-enhancing effects of glucagon agonism could result in a more favorable body composition profile, with proportionally less lean mass loss relative to fat mass loss compared to agents acting primarily through appetite suppression. This remains to be confirmed in dedicated body composition studies.

Liraglutide: The Earlier Generation GLP-1 Agonist

Historical Context

Liraglutide, also developed by Novo Nordisk, is an earlier-generation GLP-1 receptor agonist that paved the way for semaglutide. It shares 97% homology with native human GLP-1 and uses a C-16 fatty acid chain for albumin binding, yielding a half-life of approximately 13 hours that necessitates once-daily rather than once-weekly dosing.

Approved Formulations

• Victoza: Approved for type 2 diabetes. Administered as a once-daily subcutaneous injection at doses of 0.6 mg, 1.2 mg, and 1.8 mg.
• Saxenda: Approved for chronic weight management. Administered as a once-daily subcutaneous injection at a dose of 3.0 mg.

Efficacy Comparison

While liraglutide represented a significant advance when it was first approved, its efficacy is now recognized as being substantially lower than that of semaglutide and tirzepatide. In the SCALE trial program, liraglutide 3.0 mg achieved mean weight loss of approximately 8% at 56 weeks, compared to placebo weight loss of approximately 2.6%. The LEADER cardiovascular outcomes trial demonstrated a 13% reduction in MACE with liraglutide in patients with type 2 diabetes and high cardiovascular risk.

The differences in efficacy between liraglutide and semaglutide are generally attributed to semaglutide's superior pharmacokinetic profile (once-weekly dosing with sustained receptor activation versus once-daily dosing with daily peaks and troughs), potentially greater brain penetration, and higher achievable receptor occupancy.

Current Role

Liraglutide retains a role in the therapeutic landscape, particularly in pediatric populations (Saxenda is approved for adolescents aged 12 and older) and in certain markets. However, it has been largely superseded by semaglutide and tirzepatide for adult metabolic indications in settings where these newer agents are available.

Cagrilintide and CagriSema: The Amylin Combination Approach

What Is Cagrilintide?

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells that plays a complementary role to GLP-1 in metabolic regulation. Amylin slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety through activation of receptors in the area postrema and other brainstem regions.

Cagrilintide is acylated with a fatty acid chain to enable once-weekly subcutaneous administration, analogous to the engineering approach used in semaglutide. As a standalone agent, cagrilintide has demonstrated modest but significant weight loss in early clinical trials.

CagriSema: The Fixed-Ratio Combination

The most significant application of cagrilintide is in the fixed-ratio combination known as CagriSema, which combines cagrilintide with semaglutide in a single once-weekly subcutaneous injection. The rationale is that amylin and GLP-1 signaling pathways are complementary and may produce synergistic effects on appetite regulation and weight loss when activated simultaneously.

Phase 2 data for CagriSema demonstrated weight reductions of approximately 15.6% at 32 weeks in participants with overweight or obesity, exceeding the weight loss observed with either component alone at the same time point. Phase 3 trials are ongoing, and CagriSema represents Novo Nordisk's strategy for maintaining its competitive position against tirzepatide and retatrutide.

Key phase 3 results (REDEFINE program) have indicated that CagriSema may achieve weight loss in the 20-25% range at 68 weeks, which would place it competitively with tirzepatide. The combination approach of targeting two distinct satiety pathways (GLP-1 in the hypothalamus and amylin in the brainstem) may also offer advantages in terms of maintaining efficacy in patients who show diminishing response to GLP-1 agonism alone.

Survodutide: The Glucagon/GLP-1 Dual Agonist

Mechanism and Development

Survodutide (BI 456906), developed by Boehringer Ingelheim in collaboration with Zealand Pharma, is a dual agonist of glucagon and GLP-1 receptors. Unlike tirzepatide, which combines GIP and GLP-1 agonism, survodutide combines glucagon and GLP-1 agonism, offering a different balance of metabolic effects.

The glucagon component is intended to enhance energy expenditure and hepatic lipid metabolism, while the GLP-1 component provides appetite suppression and glycemic control. This combination is conceptually similar to two of the three components of retatrutide (minus the GIP agonism).

Clinical Data

Survodutide has shown particularly impressive results in liver-related outcomes. In a phase 2 trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), survodutide achieved histological improvement (resolution of steatohepatitis without worsening of fibrosis) in up to 83% of patients at the highest dose, with concurrent liver fat reductions exceeding 80% and significant improvements in fibrosis scores. These results position survodutide as one of the most promising candidates for MASH treatment.

Weight loss with survodutide has been reported at approximately 14-19% in various studies, placing it in a competitive range with semaglutide and tirzepatide. The particular strength of the glucagon/GLP-1 combination may be in conditions where hepatic fat metabolism is a primary therapeutic target.

Mazdutide: The Dual GLP-1/Glucagon Agonist from China

Overview

Mazdutide (IBI362, LY3305677), developed by Innovent Biologics in partnership with Eli Lilly, is a dual agonist of GLP-1 and glucagon receptors being developed primarily for the Chinese and broader Asian market. Like survodutide, it combines GLP-1 and glucagon receptor agonism, though the specific molecular design and receptor binding characteristics differ.

Clinical Data in Asian Populations

Mazdutide has produced noteworthy clinical data in predominantly Chinese patient populations. In phase 2 and phase 3 studies, mazdutide has achieved weight reductions in the range of 10-15% at various doses and timepoints. Mazdutide received its first regulatory approval in China in late 2024 for weight management, making it one of the earliest dual agonists to reach the market.

The development of mazdutide reflects the growing global nature of incretin-based therapeutic research and the recognition that obesity and type 2 diabetes represent enormous unmet needs in Asian populations, where metabolic disease prevalence is increasing rapidly and may manifest at lower BMI thresholds than in Western populations.

Market Significance

Mazdutide's primary commercial opportunity is in China and other Asian markets, where it may face less direct competition from Novo Nordisk and Eli Lilly products. The Chinese obesity and diabetes markets are among the largest in the world, and domestically developed treatments may have advantages in terms of pricing, availability, and regulatory pathway.

Other Emerging Compounds and Approaches

Orforglipron (Eli Lilly)

While not a peptide, orforglipron deserves mention as a non-peptide oral GLP-1 receptor agonist. Unlike Rybelsus (oral semaglutide), which requires an absorption enhancer and must be taken on an empty stomach, orforglipron is a small molecule with conventional oral bioavailability. Phase 2 data showed weight reductions of up to approximately 14.7% at 36 weeks, and phase 3 trials are underway. If successful, orforglipron could significantly improve the convenience and accessibility of GLP-1 receptor agonist therapy.

Danuglipron (Pfizer)

Another non-peptide oral GLP-1 receptor agonist, danuglipron was being developed by Pfizer. The twice-daily formulation showed moderate weight loss but significant GI tolerability issues in phase 2, leading Pfizer to focus on a modified-release once-daily formulation. The development pathway has been challenging, reflecting the difficulty of replicating the sustained receptor activation achieved by weekly injectable peptides with oral small molecules.

Pemvidutide (Altimmune)

Pemvidutide is a dual GLP-1/glucagon receptor agonist in development with a particular focus on MASH/NASH. Phase 2 data showed significant hepatic fat reduction and promising weight loss, positioning it in the growing competitive field of dual agonists targeting liver disease.

Comparative Analysis: Mechanisms Across Generations

Single vs. Dual vs. Triple Agonism

The evolution from single to dual to triple agonism reflects a broader scientific understanding that metabolic regulation involves multiple interconnected signaling pathways, and targeting several simultaneously may produce synergistic benefits:

Compound	Targets	Peak Weight Loss	Key Advantage
Liraglutide	GLP-1	~8%	Extensive long-term safety data
Semaglutide	GLP-1	~15-17%	Broadest evidence base, CV outcomes
Tirzepatide	GIP + GLP-1	~21-23%	Superior weight loss, strong glycemic control
CagriSema	Amylin + GLP-1	~20-25%	Dual satiety pathways
Survodutide	Glucagon + GLP-1	~14-19%	Exceptional liver fat reduction
Mazdutide	GLP-1 + Glucagon	~10-15%	Asian market availability
Retatrutide	GIP + GLP-1 + Glucagon	~24%+ (phase 2)	Highest weight loss, energy expenditure

Tolerability Considerations Across Compounds

Gastrointestinal side effects remain the primary tolerability concern across all GLP-1-based therapies. However, the severity and frequency may vary between compounds:

• Semaglutide: Nausea rates of approximately 20-44% during titration, generally improving with time. Established dose-escalation protocol over 16-20 weeks.
• Tirzepatide: Nausea rates of approximately 12-33% depending on dose, with some evidence suggesting that the GIP component may attenuate GLP-1-mediated nausea. The tolerability profile has been cited as a potential advantage.
• Retatrutide: Phase 2 data showed nausea rates of approximately 16-45% depending on dose and titration speed. The addition of glucagon agonism did not appear to significantly worsen GI tolerability compared to GLP-1-based agents.
• Survodutide and mazdutide: Similar GI side effect profiles to other agents in this class.

The Future Landscape: What Comes After Triple Agonism?

The trajectory from single to dual to triple agonism naturally raises the question of what might come next. Several directions are being explored:

• Quadruple and higher-order agonism: Research is exploring molecules that might target four or more receptors, though the complexity of balancing multiple agonist activities presents significant pharmacological challenges.
• Combination with non-incretin targets: Approaches combining GLP-1 agonism with targets outside the incretin system, such as activin receptor blockers (to preserve muscle mass) or central melanocortin system modulators, are under investigation.
• Precision dosing and personalization: As more compounds become available, there is growing interest in matching specific patients to specific agents based on their metabolic phenotype, comorbidity profile, and treatment goals.
• Oral and long-acting formulations: Development of oral small molecule GLP-1 agonists, monthly injectable formulations, and implantable delivery systems could improve convenience and adherence.
• Combination with surgical and device interventions: Research is exploring whether pharmacological therapy might be used to enhance, maintain, or even replace the effects of bariatric surgery in certain populations.

Conclusion: A New Era in Metabolic Medicine

The evolution from liraglutide to semaglutide to tirzepatide to retatrutide represents one of the most rapid and consequential progressions in pharmacological history. Each generation has substantially advanced the efficacy frontier, with phase 2 data for retatrutide suggesting that pharmacological weight reductions approaching 25% or more may be achievable. The field is moving from an era where the question was whether medications could produce meaningful weight loss to an era where the questions center on which metabolic pathways to target, how to optimize body composition during weight loss, how to maintain benefits long-term, and how to ensure equitable access to these transformative therapies.

For researchers and students of metabolic science, this is a field of extraordinary dynamism. The coming years will bring pivotal phase 3 data for retatrutide, CagriSema, and multiple other compounds, as well as longer-term outcome data for tirzepatide and expanded indication data for semaglutide. The competitive dynamics between Novo Nordisk, Eli Lilly, Boehringer Ingelheim, and emerging players will drive continued innovation and, hopefully, improved access for the billions of people worldwide affected by obesity and related metabolic conditions.

This article is for educational and informational purposes only. It does not constitute medical advice. Always consult with a qualified healthcare professional regarding any health-related decisions.